by Lisa Willemse | Apr 24, 2013
Co-authored with Geoff Lomax, CIRM’s Senior Officer to the Standards Working Group from the “Understanding Stem Cell Controversies” Workshop organized by the Stem Cell Network in Montreal. This article is cross-posted on the CIRM blog. “Stem cell...
by Nick Dragojlovic | Apr 23, 2013
. The U.S. Food and Drug Administration’s (FDA) ongoing efforts to assert its authority to regulate U.S.-based companies that offer unlicensed stem cell therapies (Regenerative Sciences or Celltex, for example) has prompted a mixed response from the regenerative...
by Ubaka Ogbogu | Feb 26, 2013
Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May...
by Nick Dragojlovic | Feb 20, 2013
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is...
by Paul Krzyzanowski | Feb 14, 2013
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called...
by Paul Krzyzanowski | Jan 8, 2013
This year, your household will pay $360 for the use of Intellectual Property (IP) held by people and corporations outside of Canada. For a little less than a dollar a day, you’re supporting industries like biotechnology, high-tech electronics, and engineering in other...
Comments